Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2023-04-19 | Dr. Seizinger makes valuable contribution to the Board based on his insight and vast global biopharmaceutical experience. |
| 2024-05-15 | Dr. Seizinger received his M.D. from Ludwig-Maximilians-Universität Munich, and his Ph.D. from Max-Planck-Institute of Psychiatry/Neurobiology in Munich. |
| 2024-07-17 | The table below sets forth information known to us regarding the beneficial ownership of our Shares as of July 11, 2024 for: each of our directors; ... Dr. Bernd R. Seizinger: 22,832 shares. |
| 2024-12-30 | Name of Beneficial Owner: Dr. Bernd R. Seizinger |
Data sourced from SEC filings. Last updated: 2025-08-24